Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALI MOHAMMAD ALSAADI

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1912941477
CMS profile
177182
Location
FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,373.51

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,351.77 75
Education $21.74 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALI MOHAMMAD ALSAADI

NPI 1912941477 · CMS profile ID 177182

Allopathic & Osteopathic Physicians / Internal Medicine

FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912941477?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALI MOHAMMAD ALSAADI, NPI 1912941477, CMS profile ID 177182. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912941477?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ALI MOHAMMAD ALSAADI, NPI 1912941477, CMS profile ID 177182. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912941477?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ALI MOHAMMAD ALSAADI, NPI 1912941477, CMS profile ID 177182, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1912941477?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $1,373.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $14.5805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827755055 CMS
Astellas Pharma US Inc $24.3605/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821245939 CMS
SANOFI-AVENTIS U.S. LLC $12.7105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843602525 CMS
DEXCOM, INC. $15.8604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845267579 CMS
Teva Pharmaceuticals USA, Inc. $17.1004/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839643893 CMS
Astellas Pharma US Inc $24.2804/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821245935 CMS
Janssen Pharmaceuticals, Inc $12.4304/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788818767 CMS
E.R. Squibb & Sons, L.L.C. $18.3903/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783620481 CMS
AstraZeneca Pharmaceuticals LP $21.6103/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829887145 CMS
Merck Sharp & Dohme Corporation $18.5603/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848483165 CMS
GlaxoSmithKline, LLC. $16.1903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803029675 CMS
Nestle HealthCare Nutrition Inc. $20.4603/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820867681 CMS
Aprecia Pharmaceuticals, LLC $12.9103/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819741417 CMS
AstraZeneca Pharmaceuticals LP $12.7203/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829640703 CMS
Biogen, Inc. $19.3203/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827755053 CMS
Novartis Pharmaceuticals Corporation $13.7902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812585509 CMS
Novartis Pharmaceuticals Corporation $15.6602/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812585511 CMS
GlaxoSmithKline, LLC. $13.2602/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802360339 CMS
PFIZER INC. $25.3702/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832751317 CMS
Nestle HealthCare Nutrition Inc. $15.7702/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820867677 CMS
Teva Pharmaceuticals USA, Inc. $17.4501/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839643891 CMS
AstraZeneca Pharmaceuticals LP $16.4901/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830269301 CMS
E.R. Squibb & Sons, L.L.C. $12.3001/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783620465 CMS
Eisai Inc. $23.5801/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817814411 CMS
Indivior Inc. $20.5701/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835079167 CMS
AbbVie Inc. $11.5901/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793866857 CMS
Novartis Pharmaceuticals Corporation $12.3901/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812585507 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $948.19 43
PY2020 $187.35 12
PY2021 $1,373.51 77
PY2022 $1,208.98 71
PY2023 $1,019.62 42
PY2024 $767.90 36
PY2025 $897.18 39

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,832.33 142
PY2024 Principal investigator $4,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288130
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288132
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288134
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288136
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288138
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288140
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288142
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288144
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288146
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288148
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288150
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288152
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288154
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288156
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288158
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288160
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288162
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288164
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288166
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288168
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288170
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288172
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288174
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288344
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288346
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288348
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288350
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288352
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288354
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288356
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288368
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288370
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288372
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288374
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288376
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288378
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288380
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288588
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288590
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288592
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288594
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288596
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288598
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288600
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288602
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288604
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288606
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288608
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288610
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288612
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288614
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288616
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288618
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288620
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288622
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288624
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288626
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288628
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288630
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288632
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288634
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288636
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288638
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288640
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288642
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288644
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288646
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288648
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288650
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288652
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288654
Principal investigator 1 Seqirus USA Inc $472.50 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288792
Principal investigator 1 Seqirus USA Inc $945.00 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288794
Principal investigator 1 Seqirus USA Inc $1,352.40 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288798
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288800
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288802
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288804
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288806
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288808
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288810
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288812
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288814
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288816
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288818
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288820
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288822
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288824
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288826
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288828
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288830
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288832
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288834
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288836
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288838
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288840
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288842
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288844
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288846
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288849
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288852
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288854
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288856
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288858
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288860
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288862
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288864
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288866
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288868
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288870
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288872
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288874
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288876
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288878
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288880
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288882
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288884
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288886
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288888
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288890
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288892
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288894
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288896
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288898
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288900
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288902
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288904
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288906
Principal investigator 1 Seqirus USA Inc $4,062.10 12/18/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185288908
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,300.00 11/26/2025 Non-covered Recipient Entity
BIOSCOPE CLINICAL RESEARCH LLC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185544051
Principal investigator 1 Seqirus USA Inc $3,000.00 11/13/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290284
Principal investigator 1 Seqirus USA Inc $13,500.00 11/13/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290298
Principal investigator 1 Seqirus USA Inc $2,564.40 11/12/2025 Non-covered Recipient Entity
Bioscope Clinical Research, LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811114
Principal investigator 1 Seqirus USA Inc $704.70 11/12/2025 Non-covered Recipient Entity
Bioscope Clinical Research, LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811118
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,641.05 11/05/2025 Non-covered Recipient Entity
BIOSCOPE CLINICAL RESEARCH LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185544047
Principal investigator 1 Seqirus USA Inc $2,564.40 10/31/2025 Non-covered Recipient Entity
Bioscope Clinical Research, LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811105
Principal investigator 1 Seqirus USA Inc $704.70 10/31/2025 Non-covered Recipient Entity
Bioscope Clinical Research, LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811110
Principal investigator 1 Seqirus USA Inc $3,000.00 10/16/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290282
Principal investigator 1 Seqirus USA Inc $13,500.00 10/16/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290300
Principal investigator 1 Seqirus USA Inc $110.98 09/12/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290218
Principal investigator 1 Seqirus USA Inc $111.30 09/12/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290222
Principal investigator 1 Seqirus USA Inc $946.80 09/12/2025 Non-covered Recipient Entity
Pharmaseek LLC
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290264
Principal investigator 1 Ferring Pharmaceuticals AS $1,000.00 08/27/2025 Non-covered Recipient Entity
BIOSCOPE CLINICAL RESEARCH
REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study No dispute reported 06/30/2026 1242060890